CN109198619A - A kind of composition and its application with raising fecundity effect - Google Patents
A kind of composition and its application with raising fecundity effect Download PDFInfo
- Publication number
- CN109198619A CN109198619A CN201811128739.5A CN201811128739A CN109198619A CN 109198619 A CN109198619 A CN 109198619A CN 201811128739 A CN201811128739 A CN 201811128739A CN 109198619 A CN109198619 A CN 109198619A
- Authority
- CN
- China
- Prior art keywords
- parts
- composite powder
- composition
- vitamin
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 230000035558 fertility Effects 0.000 title claims abstract description 73
- 230000000694 effects Effects 0.000 title claims abstract description 62
- 239000002131 composite material Substances 0.000 claims abstract description 128
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 115
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 74
- 235000019152 folic acid Nutrition 0.000 claims abstract description 64
- 239000011724 folic acid Substances 0.000 claims abstract description 64
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 56
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 54
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 51
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 51
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 51
- 239000011710 vitamin D Substances 0.000 claims abstract description 51
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 51
- 229940046008 vitamin d Drugs 0.000 claims abstract description 51
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 50
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 30
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 30
- 235000012661 lycopene Nutrition 0.000 claims abstract description 30
- 229960004999 lycopene Drugs 0.000 claims abstract description 30
- 239000001751 lycopene Substances 0.000 claims abstract description 30
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 30
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 30
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims abstract description 30
- 235000006076 zinc citrate Nutrition 0.000 claims abstract description 30
- 229940068475 zinc citrate Drugs 0.000 claims abstract description 30
- 239000011746 zinc citrate Substances 0.000 claims abstract description 30
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 28
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 28
- 229940046009 vitamin E Drugs 0.000 claims abstract description 28
- 239000011709 vitamin E Substances 0.000 claims abstract description 28
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 27
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 27
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 27
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 25
- 239000011718 vitamin C Substances 0.000 claims abstract description 25
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 229940064302 folacin Drugs 0.000 claims abstract description 13
- -1 folacin compound Chemical class 0.000 claims abstract description 13
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 136
- 235000013312 flour Nutrition 0.000 claims description 88
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 51
- 229960000304 folic acid Drugs 0.000 claims description 51
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 22
- 235000020778 linoleic acid Nutrition 0.000 claims description 22
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 3
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 claims description 2
- NRGONRDRXCPMIC-GDKBPFBDSA-N N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CC(C=O)C(O)=O)C(O)=O)C=C1 Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CC(C=O)C(O)=O)C(O)=O)C=C1 NRGONRDRXCPMIC-GDKBPFBDSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 229960003208 levomefolic acid Drugs 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 16
- 208000037093 Menstruation Disturbances Diseases 0.000 abstract description 10
- 206010027339 Menstruation irregular Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000007423 decrease Effects 0.000 abstract description 8
- 230000003750 conditioning effect Effects 0.000 abstract description 7
- 208000035475 disorder Diseases 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 7
- 210000001672 ovary Anatomy 0.000 abstract description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract description 2
- 238000010237 hybrid technique Methods 0.000 abstract 1
- 239000011669 selenium Substances 0.000 description 66
- 230000000052 comparative effect Effects 0.000 description 22
- 229960004232 linoleic acid Drugs 0.000 description 21
- 239000011812 mixed powder Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 8
- 230000027758 ovulation cycle Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 206010016256 fatigue Diseases 0.000 description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 5
- 229910052711 selenium Inorganic materials 0.000 description 5
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000021267 infertility disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000750 endocrine system Anatomy 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000017701 Endocrine disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of with the composition and preparation method thereof for improving fecundity effect, it is by by lycopene, Se-enriched yeast, zinc citrate, folacin compound, vitamin D, vitamin E is combined with special ratios, the composition material further includes alpha-linolenic acid, linoleic acid, one or more of haematococcus pluvialis and vitamin C, the effect of each substance is preferably played by the synergy between each raw material, gradient hybrid technique is used in preparation method of the present invention, by a series of preparation processes by raw material after mixing up to described a kind of with the composition for improving fecundity effect.The composition has the function of that conditioning improves to female endocrinic disorders, irregular menstruation and hypofunction of ovary symptom, has preferable improvement to the women for causing fecundity to decline because of age increase simultaneously.
Description
Technical field
The present invention relates to technical field of health care food more particularly to it is a kind of with improve fecundity effect composition and
Using.
Background technique
With the raising of people's quality of life level, people's lives idea is also constantly open, no longer contents just to clothing
Eat carefree, property demand is more and more paid close attention to as a kind of original instinct of the mankind by people, due to the universal of computer and
Nervous study and work etc. makes people by various intentional or unintentional sign stimulus and various tangible or invisible spirit pressures
Power causes people often in fatigue even over fatigue state.Fatigue is the main reason for causing sex dysfunction；And property function
Fatigue symptom is also further aggravated in energy obstacle.Showing China at present according to statistics has people more than half to be in confirmed fatigue
The state of syndrome accounts for about 70% in urban population, and China has 500,000,000 or more population to be in sub-health state in theory,
And this ratio is constantly increasing.
Health care has become the thing increasingly paid attention in people's life, and people increasingly value health.It is strong
The human body of health is the metabolism and physiological function for adjusting human body together by the various hormones of endocrine system (hormone) and nervous system.
Endocrine system participates in adjusting many physiological activities and the biological phenomenas such as metabolic process, growth and development, the reproduction aging of human body, association
The relative stability of human internal environment is maintained, with various ferment (biochemical enzymes) to adapt to inside and outside variation complicated and changeable.
When human body is influenced by factors such as environment, psychology, physiology, mood, nutrition, endocrine system gets muddled, with
Just will appear various signs, especially women, symptom becomes apparent, occur such as skin deteriorate, short-tempered, gynaecology's disease
Phenomena such as sick, fat, infertile, white hair, early ageing.In addition, the secretion of endocrine disorder, especially sex hormone is reduced, and lead to people
The major reason of body aging.
Also, simultaneously because the reasons such as job and life stress, environmental pollution and bad habit of individual, cause compatriots sub-
Healthy ratio is growing, and produces biggish negative effect to the fecundity of the mankind, so that the infertile rate of the mankind occupies
It is high not under, according to incompletely statistics, the infertile patient in the whole nation is more than 40,000,000 people at present, seriously affects the happy family life of compatriots.
A kind of Chinese medicine composition is disclosed in Chinese patent application 201610061131.X, be can be used as auxiliary material and is added to
In animal food, play the role of improving fertility and anti-aging, constitutional；Chinese patent application
A kind of maca composition containing Fructus Corni and Qi-tonifying drug is disclosed in 201510132781.4, is used to improve sexual function, is alleviated
Fatigue improves fecundity；But the above patent is not concerned about to female endocrinic disorders, irregular menstruation and ovarian function
The conditioning and treating function of low symptom, and there is the product for improving fecundity currently on the market, dependence with higher,
It needs to take for a long time, and the effect for being used as raising fecundity is poor, especially causes fecundity to decline to because of age increase
Women, therapeutic effect are weak.
Based on above-mentioned realistic problem, those skilled in the art are dedicated to disclosing a kind of with the group for improving fecundity effect
Object is closed, so that reaching has the function of improving the symptoms such as female endocrinic disorders, irregular menstruation and hypofunction of ovary, together
When to which there is stronger therapeutic effect to the women for causing fecundity to decline because of age increase, thus the present invention generates.
Summary of the invention
The purpose of the present invention is to provide a kind of with the composition of fecundity effect is improved, and changes so that reaching and having
The purpose of the symptoms such as kind female endocrinic disorders, irregular menstruation and hypofunction of ovary, it is another object of the present invention to
Reaching has preferable improvement to the women for causing fecundity to decline because of age increase.
To achieve the goals above, the present invention provides the following technical scheme that
A kind of composition with raising fecundity effect, it is characterised in that: the composition includes following weight
The raw material of part: 5-600 parts of lycopene, 0.05-150 parts of Se-enriched yeast, 0.05-50 parts of zinc citrate, folacin compound
0.05-1 parts, 0.00005-0.07 parts of vitamin D, 0.05-300 parts of vitamin E.
Preferably, the composition includes the raw material of following parts by weight: 10-500 parts of lycopene, Se-enriched yeast 0.1-
100 parts, 0.1-40 parts of zinc citrate, 0.1-0.8 parts of folacin compound, 0.0001-0.05 parts of vitamin D, vitamin E
0.1-200 parts.
The folacin compound is folic acid, formyl tetrahydrofolic acid, metafolin, folic acid officinal salt, folic acid or leaf
It the active metabolite of sour officinal salt and can be metabolized in vivo and/or one or more of the substance for generating folic acid.
Further, the folacin compound is preferably folic acid.
The composition material further includes one of alpha-linolenic acid, linoleic acid, haematococcus pluvialis and vitamin C or several
Kind.
Further, the content of the alpha-linolenic acid is 50-8000 parts.
Further, the linoleic content is 50-10000 parts.
Further, the content of the haematococcus pluvialis is 0.05-1000 parts.
Further, the ascorbic content is 0.05-500 parts.
The above-mentioned preparation method with the composition for improving fecundity effect, includes the following steps:
(1) lycopene, zinc citrate, vitamin C, vitamin E and the haematococcus pluvialis for weighing recipe quantity are premixed,
Incorporation time 10min obtains composite powder 1；
(2) vitamin D, folacin compound are carried out gradient with Se-enriched yeast to mix, obtains composite powder 2；
(3) composite powder 1 is carried out gradient with composite powder 2 to mix, obtains composite powder 3；
(4) composite powder 3 and alpha-linolenic acid, linoleic acid are subjected to total mix, incorporation time 30min, after mixing up to institute
It states a kind of with the composition for improving fecundity effect.
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folacin compound are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；Institute
The gross mass for stating vitamin D, folacin compound is equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 with it is multiple
The quality for closing powder 2 is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；By the 4th premixing flour
It is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
Heretofore described has the composition for improving fecundity effect, and dosage form can be pulvis or tablet.When this
When product is pulvis, formula includes composition in above-mentioned technical proposal and weight percent is the acid of 1-5%, weight
The glidant that the sweetener and weight percent that percentage is 1-15% are 1-5%.
The acid is selected from one or more of citric acid, lactic acid and malic acid.
The sweetener is selected from one or more of xylitol, D-sorbite, stachyose and Aspartame.
The glidant is selected from one or more of silica, calcium silicates and calcium monohydrogen phosphate.
The advantages and positive effects of the present invention are: the present invention provides a kind of with the combination for improving fecundity effect
Object and its preparation method and application, the product have female endocrinic disorders, irregular menstruation and hypofunction of ovary symptom
Conditioning improves function, has preferable improvement, the present invention to the women for causing fecundity to decline because of age increase simultaneously
Thus it generates.
Specific embodiment
The present invention can further be well understood by specific examples presented below, but they are not to the present invention
Restriction.
Embodiment 1
A kind of composition with raising fecundity effect includes the raw material of following parts by weight: 175 parts of lycopene, richness
15 parts of selenium yeast, 22.5 parts of zinc citrate, 0.24 part of folic acid, 0.01 part of vitamin D, 40 parts of vitamin E, haematococcus pluvialis
300 parts, 55 parts of vitamin C, 3000 parts of alpha-linolenic acid and 4000 parts of linoleic acid.
The above-mentioned preparation method with the composition for improving fecundity effect, comprising the following steps:
(1) lycopene, zinc citrate, vitamin C, vitamin E and the haematococcus pluvialis of weight content in formula are weighed
Premix 10min is carried out, composite powder 1 is obtained；
(2) Se-enriched yeast is carried out gradient with folic acid, vitamin D to mix, obtains composite powder 2；
(3) the resulting composite powder 1 of step (1) is carried out gradient with the resulting composite powder 2 of step (2) to mix, obtains mixed powder
3；
(4) mixed powder 3 and alpha-linolenic acid, linoleic acid are subjected to total mix, after mixing up to composition.
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folic acid are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；The vitamin
D, the gross mass of folic acid is equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 with it is multiple
The quality for closing powder 2 is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；
4th premixing flour is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
Embodiment 2
A kind of composition with raising fecundity effect includes the raw material of following parts by weight: 10 parts of lycopene, richness
0.1 part of selenium yeast, 0.1 part of zinc citrate, 0.1 part of folic acid, 0.0001 part of vitamin D, 0.1 part of vitamin E, haematococcus pluvialis
0.1 part, 0.1 part of vitamin C, 100 parts of alpha-linolenic acid and 100 parts of linoleic acid.
The above-mentioned preparation method with the composition for improving fecundity effect, comprising the following steps:
(1) lycopene, zinc citrate, vitamin C, vitamin E and the haematococcus pluvialis of weight content in formula are weighed
Premix 10min is carried out, composite powder 1 is obtained；
(2) Se-enriched yeast is carried out gradient with folic acid, vitamin D to mix, obtains composite powder 2；
(3) the resulting composite powder 1 of step (1) is carried out gradient with the resulting composite powder 2 of step (2) to mix, obtains mixed powder
3；
(4) mixed powder 3 and alpha-linolenic acid, linoleic acid are subjected to total mix, after mixing up to composition.
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folic acid are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；The vitamin
D, the gross mass of folic acid is equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 with it is multiple
The quality for closing powder 2 is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；
4th premixing flour is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
Embodiment 3
A kind of composition with raising fecundity effect includes the raw material of following parts by weight: 500 parts of lycopene, richness
100 parts of selenium yeast, 40 parts of zinc citrate, 0.8 part of folic acid, 0.05 part of vitamin D, 200 parts of vitamin E, haematococcus pluvialis 800
Part, 200 parts of vitamin C, 5000 parts of alpha-linolenic acid and 8000 parts of linoleic acid.
The above-mentioned preparation method with the composition for improving fecundity effect, comprising the following steps:
(1) lycopene, zinc citrate, vitamin C, vitamin E and the haematococcus pluvialis of weight content in formula are weighed
Premix 10min is carried out, composite powder 1 is obtained；
(2) Se-enriched yeast is carried out gradient with folic acid, vitamin D to mix, obtains composite powder 2；
(3) the resulting composite powder 1 of step (1) is carried out gradient with the resulting composite powder 2 of step (2) to mix, obtains mixed powder
3；
(4) mixed powder 3 and alpha-linolenic acid, linoleic acid are subjected to total mix, after mixing up to composition.
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folic acid are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；The vitamin
D, the gross mass of folic acid is equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 with it is multiple
The quality for closing powder 2 is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；
4th premixing flour is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
Embodiment 4
A kind of composition with raising fecundity effect includes the raw material of following parts by weight: 5 parts of lycopene, selenium-rich
0.05 part of yeast, 0.05 part of zinc citrate, 0.05 part of folic acid, 0.00005 part of vitamin D, 0.05 part of vitamin E, rain life are red
0.05 part of ball algae, 0.05 part of vitamin C, 50 parts of alpha-linolenic acid and 50 parts of linoleic acid.
The above-mentioned preparation method with the composition for improving fecundity effect, comprising the following steps:
(1) lycopene, zinc citrate, vitamin C, vitamin E and the haematococcus pluvialis of weight content in formula are weighed
Premix 10min is carried out, composite powder 1 is obtained；
(2) Se-enriched yeast is carried out gradient with folic acid, vitamin D to mix, obtains composite powder 2；
(3) the resulting composite powder 1 of step (1) is carried out gradient with the resulting composite powder 2 of step (2) to mix, obtains mixed powder
3；
(4) mixed powder 3 and alpha-linolenic acid, linoleic acid are subjected to total mix, after mixing up to composition.
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folic acid are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；The vitamin
D, the gross mass of folic acid is equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 with it is multiple
The quality for closing powder 2 is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；
4th premixing flour is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
Embodiment 5
A kind of composition with raising fecundity effect includes the raw material of following parts by weight: 600 parts of lycopene, richness
150 parts of selenium yeast, 50 parts of zinc citrate, 1 part of folic acid, 0.07 part of vitamin D, 300 parts of vitamin E, haematococcus pluvialis 1000
Part, 500 parts of vitamin C, 8000 parts of alpha-linolenic acid and 10000 parts of linoleic acid.
The above-mentioned preparation method with the composition for improving fecundity effect, comprising the following steps:
(1) lycopene, zinc citrate, vitamin C, vitamin E and the haematococcus pluvialis of weight content in formula are weighed
Premix 10min is carried out, composite powder 1 is obtained；
(2) Se-enriched yeast is carried out gradient with folic acid, vitamin D to mix, obtains composite powder 2；
(3) the resulting composite powder 1 of step (1) is carried out gradient with the resulting composite powder 2 of step (2) to mix, obtains mixed powder
3；
(4) mixed powder 3 and alpha-linolenic acid, linoleic acid are subjected to total mix, after mixing up to composition.
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folic acid are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；The vitamin
D, the gross mass of folic acid is equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 with it is multiple
The quality for closing powder 2 is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；
4th premixing flour is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
Embodiment 6
The difference from embodiment 1 is that: it is described it is a kind of with improve fecundity effect composition include following weight
Part raw material: 175 parts of lycopene, 15 parts of Se-enriched yeast, 22.5 parts of zinc citrate, 0.24 part of folic acid, 0.01 part of vitamin D,
40 parts of vitamin E, 300 parts of haematococcus pluvialis, 55 parts of vitamin C and 3000 parts of alpha-linolenic acid.
The above-mentioned preparation method with the composition for improving fecundity effect, comprising the following steps:
(1) lycopene, zinc citrate, vitamin C, vitamin E and the haematococcus pluvialis of weight content in formula are weighed
Premix 10min is carried out, composite powder 1 is obtained；
(2) Se-enriched yeast is carried out gradient with folic acid, vitamin D to mix, obtains composite powder 2；
(3) the resulting composite powder 1 of step (1) is carried out gradient with the resulting composite powder 2 of step (2) to mix, obtains mixed powder
3；
(4) mixed powder 3 and alpha-linolenic acid are subjected to total mix, after mixing up to composition.
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folic acid are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；The vitamin
D, the gross mass of folic acid is equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 with it is multiple
The quality for closing powder 2 is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；
4th premixing flour is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
Embodiment 7
The difference from embodiment 1 is that: it is described a kind of with the composition for improving fecundity effect, including following weight
Part raw material: 175 parts of lycopene, 15 parts of Se-enriched yeast, 22.5 parts of zinc citrate, 0.24 part of folic acid, 0.01 part of vitamin D,
40 parts of vitamin E, 300 parts of haematococcus pluvialis, 55 parts of vitamin C and 4000 parts of linoleic acid.
The above-mentioned preparation method with the composition for improving fecundity effect, comprising the following steps:
(1) lycopene, zinc citrate, vitamin C, vitamin E and the haematococcus pluvialis of weight content in formula are weighed
Premix 10min is carried out, composite powder 1 is obtained；
(2) Se-enriched yeast is carried out gradient with folic acid, vitamin D to mix, obtains composite powder 2；
(3) the resulting composite powder 1 of step (1) is carried out gradient with the resulting composite powder 2 of step (2) to mix, obtains mixed powder
3；
(4) mixed powder 3 and linoleic acid are subjected to total mix, after mixing up to composition.
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folic acid are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；The vitamin
D, the gross mass of folic acid is equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 with it is multiple
The quality for closing powder 2 is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；
4th premixing flour is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
Embodiment 8
The difference from embodiment 1 is that: it is described a kind of with the composition for improving fecundity effect, including following weight
Part raw material: 175 parts of lycopene, 15 parts of Se-enriched yeast, 22.5 parts of zinc citrate, 0.24 part of folic acid, 0.01 part of vitamin D,
40 parts of vitamin E, 300 parts of haematococcus pluvialis, 3000 parts of alpha-linolenic acid and 4000 parts of linoleic acid.
The above-mentioned preparation method with the composition for improving fecundity effect, comprising the following steps:
(1) lycopene, zinc citrate, vitamin E and the haematococcus pluvialis for weighing weight content in formula are premixed
10min obtains composite powder 1；
(2) Se-enriched yeast is carried out gradient with folic acid, vitamin D to mix, obtains composite powder 2；
(3) the resulting composite powder 1 of step (1) is carried out gradient with the resulting composite powder 2 of step (2) to mix, obtains mixed powder
3；
(4) mixed powder 3 and alpha-linolenic acid, linoleic acid are subjected to total mix, after mixing up to composition.
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folic acid are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；The vitamin
D, the gross mass of folic acid is equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 with it is multiple
The quality for closing powder 2 is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；
4th premixing flour is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
Embodiment 9
The difference from embodiment 1 is that: it is described a kind of with the composition for improving fecundity effect, including following weight
Part raw material: 175 parts of lycopene, 15 parts of Se-enriched yeast, 22.5 parts of zinc citrate, 0.24 part of folic acid, 0.01 part of vitamin D,
40 parts of vitamin E, 55 parts of vitamin C, 3000 parts of alpha-linolenic acid and 4000 parts of linoleic acid.
The above-mentioned preparation method with the composition for improving fecundity effect, comprising the following steps:
(1) lycopene, zinc citrate, vitamin E and the vitamin C for weighing weight content in formula are premixed
10min obtains composite powder 1；
(2) Se-enriched yeast is carried out gradient with folic acid, vitamin D to mix, obtains composite powder 2；
(3) the resulting composite powder 1 of step (1) is carried out gradient with the resulting composite powder 2 of step (2) to mix, obtains mixed powder
3；
(4) mixed powder 3 and alpha-linolenic acid, linoleic acid are subjected to total mix, after mixing up to composition.
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folic acid are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；The vitamin
D, the gross mass of folic acid is equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 with it is multiple
The quality for closing powder 2 is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；
4th premixing flour is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
Comparative example 1
The difference from embodiment 1 is that: it is a kind of with improve fecundity effect composition include following parts by weight
Raw material: 3 parts of lycopene, 0.03 part of Se-enriched yeast, 0.03 part of zinc citrate, 0.03 part of folic acid, 0.00002 part of vitamin D,
0.02 part of vitamin E, 0.03 part of haematococcus pluvialis, 0.02 part of vitamin C, 20 parts of alpha-linolenic acid and 30 parts of linoleic acid.
Comparative example 2
The difference from embodiment 1 is that: it is a kind of with improve fecundity effect composition include following parts by weight
Raw material: 700 parts of lycopene, 200 parts of Se-enriched yeast, 70 parts of zinc citrate, 2 parts of folic acid, 0.08 part of vitamin D, vitamin E
400 parts, 1200 parts of haematococcus pluvialis, 600 parts of vitamin C, 10000 parts of alpha-linolenic acid and 15000 parts of linoleic acid.
Comparative example 3
The difference from embodiment 1 is that: it is a kind of with improve fecundity effect composition include following parts by weight
Raw material: 175 parts of lycopene, 15 parts of Se-enriched yeast, 22.5 parts of zinc citrate, 0.24 part of folic acid, 0.01 part of vitamin D, dimension life
40 parts of plain E, 300 parts of caproic acid, 55 parts of octanoic acid, 3000 parts of alpha-linolenic acid and 4000 parts of linoleic acid.
Comparative example 4
The difference from embodiment 1 is that: it is a kind of with improve fecundity effect composition include following parts by weight
Raw material: 175 parts of lycopene, 15 parts of Se-enriched yeast, 22.5 parts of zinc citrate, 0.24 part of folic acid, 0.01 part of vitamin D, dimension life
40 parts of plain E, 300 parts of haematococcus pluvialis, 55 parts of stearic acid, 3000 parts of capric acid and 4000 parts of linoleic acid.
Compliance test result
(1) conditioning improves functional verification
Instructions of taking:
This composition human body recommended amounts are everyone daily 8g (0.13g/kg), and once a day, warm water is taken after reconstituting.
Improvement standard is as follows:
Recovery from illness: clinical symptoms disappear substantially, menstrual flow, chromaticness, period restore normally, to maintain 3 more than the menstrual cycle.
It is effective: clinical symptoms be improved significantly, the menstrual cycle postpone < 14 days, obviously increased more in the past through measuring.Chromaticness
It is obviously improved, and maintenance 3 is more than the menstrual cycle.
Effective: menstrual flow is increased, and the menstrual cycle postpones < 14 days, and clinical symptoms take a favorable turn, but fail lasting 3
Menstrual cycle.
Invalid: menstrual flow, chromaticness, period, which have no, to be substantially change, and clinical symptoms are not improved or aggravate.
Using the composition with raising fecundity effect made from embodiment 1-5 and comparative example 1-2 to 140 patients
It is as follows as the result is shown after (every group 20) carry out the taking of 3 menstrual cycles:
Table 1
| Embodiment | Recovery from illness | It is effective | Effectively | In vain |
| Embodiment 1 | 18 | 1 | 1 | 0 |
| Embodiment 2 | 16 | 2 | 1 | 1 |
| Embodiment 3 | 16 | 1 | 1 | 2 |
| Embodiment 4 | 15 | 2 | 2 | 1 |
| Embodiment 5 | 14 | 3 | 1 | 2 |
| Comparative example 1 | 8 | 4 | 5 | 3 |
| Comparative example 2 | 9 | 4 | 4 | 3 |
As seen from the above table, using the composition with raising fecundity effect made from 1-5 of the embodiment of the present invention to female
Property the symptoms such as endocrine disturbance, irregular menstruation have the function of that stronger conditioning improves；And comparative example 1-2 is to irregular menstruation illness
Improvement is obviously weak.
Using the composition pair made from embodiment 1, embodiment 6-9 and comparative example 3-4 with raising fecundity effect
It is as follows as the result is shown after (every group 20) 3 menstrual cycles of progress of 140 patients take:
Table 2
| Embodiment | Recovery from illness | It is effective | Effectively | In vain |
| Embodiment 1 | 18 | 1 | 1 | 0 |
| Embodiment 6 | 15 | 3 | 1 | 1 |
| Embodiment 7 | 13 | 2 | 3 | 2 |
| Embodiment 8 | 14 | 1 | 2 | 3 |
| Embodiment 9 | 15 | 2 | 1 | 2 |
| Comparative example 3 | 10 | 3 | 4 | 3 |
| Comparative example 4 | 9 | 5 | 4 | 2 |
As seen from the above table, during preparation has the composition for improving fecundity effect in the present invention, further add
When the raw material added is one or more of alpha-linolenic acid, linoleic acid, haematococcus pluvialis and vitamin C, composition pair obtained
The symptoms such as female endocrinic disorders, irregular menstruation have the function of that stronger conditioning improves；And the raw material that ought further add is pair
When raw material described in ratio 3-4, composition obtained is obvious to the improvement of the illnesss such as irregular menstruation, endocrine disorder
It is weak.
Statistical analysis is carried out using SPSS17.0 software package, as shown in table 3 below, by described in 1-5 of the embodiment of the present invention
There is the composition for improving fecundity effect to take after, basic Antral follicles mesh ratio take it is preceding risen, difference has system
Meter learns meaning (P < 0.05).
Table 3
| Embodiment | Before taking (basic Antral follicles mesh) | After taking (basic Antral follicles mesh) | P value |
| Embodiment 1 | 4.524±2.225 | 9.711±3.365 | < 0.05 |
| Embodiment 2 | 4.235±2.325 | 8.435±3.246 | < 0.05 |
| Embodiment 3 | 4.145±3.125 | 9.112±4.126 | < 0.05 |
| Embodiment 4 | 4.224±2.687 | 8.224±3.278 | < 0.05 |
| Embodiment 5 | 4.432±2.489 | 7.335±4.455 | < 0.05 |
| Comparative example 1 | 4.356±3.289 | 5.455±3.656 | < 0.05 |
| Comparative example 2 | 4.124±4.525 | 6.552±2.268 | < 0.05 |
As can be seen from the above table, composition made from embodiment 1-5 increases basic Antral follicles mesh significantly in the present invention
It is more, increase degree and be apparently higher than comparative example 1-2, therefore deduces that, it is produced by the present invention a kind of with raising fecundity work
Composition is curative for effect and without side-effects to ovarian function decline is improved.
(2) fecundity compliance test result is improved
In order to prove composition provided by the invention raising fecundity effect, applicant use the embodiment of the present invention
1-9 and comparative example 1-4 carries out clinical test, improves because age increase causes fecundity decline to women 260 of infertility,
Significant in efficacy, particulars are as follows:
260 are atocia special outpatient clinic patient, and diagnosis meets following standard: the age is 37-43 years old, average age
It is 40 years old, does not take contraceptives, and exclude other organic diseases, companion's fecundity is normal.Instructions of taking: to 180
Because age increase causes fecundity decline to infertile female test, allows it to take embodiment 1-9 (every group 20) and be made
Composition, dosage is everyone daily 8g (0.13g/kg), and once a day, warm water is taken after reconstituting, each course for the treatment of be 20
It, takes 3 course for the treatment of.
And to remaining 80 patients, so that it is taken composition made from comparative example 1-4 (every group 20), dosage is for everyone
Daily 8g (0.13g/kg), once a day, warm water is taken after reconstituting, and each course for the treatment of is 20 days, takes 3 course for the treatment of.
Curative effect judging standard
Recovery from illness: symptom disappears, wife's side pregnancy.
Effective: endocrine manifestations are improved than before.
Invalid: clinical symptoms are without significant change, unpregnancy.
As a result as follows:
Table 4
| Embodiment | Recovery from illness | Effectively | In vain |
| Embodiment 1 | 4 | 16 | 0 |
| Embodiment 2 | 3 | 15 | 2 |
| Embodiment 3 | 3 | 14 | 3 |
| Embodiment 4 | 2 | 15 | 3 |
| Embodiment 5 | 1 | 16 | 3 |
| Embodiment 6 | 2 | 15 | 3 |
| Embodiment 7 | 1 | 16 | 3 |
| Embodiment 8 | 2 | 14 | 4 |
| Embodiment 9 | 1 | 16 | 3 |
| Comparative example 1 | 0 | 12 | 8 |
| Comparative example 2 | 1 | 10 | 9 |
| Comparative example 3 | 1 | 11 | 8 |
| Comparative example 4 | 0 | 13 | 7 |
Comprehensive therapeutic effect:
(1) 180 is taken the patient of composition made from embodiment 1-9: 19 (10.6%) of recovery from illness, and effective 137
(76.1%), invalid 24 (13.3%), total effective rate are as follows: 86.7%；
(2) 60 are taken the patient of composition made from comparative example 1-4: 2 (2.5%) of recovery from illness, and effective 46
(57.5%), invalid 32 (40%), total effective rate are as follows: 60%.
It can thus be seen that being made because age increase causes the female patient of infertility to be taken using 1-9 of the embodiment of the present invention
Composition, effective percentage reaches 86.7%.And composition made from comparative example 1-4 is taken, effective percentage is only 60%.It says
The bright composition with raising fecundity effect only provided by the invention just has splendid raising fecundity effect, passes through
Lycopene, Se-enriched yeast, zinc citrate, folic acid, vitamin D, vitamin E are combined with special ratios, while into one
Step addition haematococcus pluvialis, vitamin C, alpha-linolenic acid and linoleic acid, are preferably sent out by the synergy between each raw material
The effect of each substance is waved, to have conditioning to improve female endocrinic disorders, irregular menstruation and hypofunction of ovary symptom
Function, while there is preferable improvement to the women for causing fecundity to decline because of age increase, improve the fertility of women
Ability.
It is emphasized that the present invention includes being not limited to embodiment described in specific embodiment, it is all by ability
The other embodiments that field technique personnel obtain according to the technique and scheme of the present invention, also belong to the scope of protection of the invention.
Claims (10)
1. a kind of with the composition for improving fecundity effect, it is characterised in that: the composition includes following parts by weight
Raw material: 5-600 parts of lycopene, 0.05-150 parts of Se-enriched yeast, 0.05-50 parts of zinc citrate, folacin compound 0.05-
1 part, 0.00005-0.07 parts of vitamin D, 0.05-300 parts of vitamin E.
2. according to claim 1 a kind of with the composition for improving fecundity effect, it is characterised in that: the group
Close object include following parts by weight raw material: 10-500 parts of lycopene, 0.1-100 parts of Se-enriched yeast, 0.1-40 parts of zinc citrate,
0.1-0.8 parts of folacin compound, 0.0001-0.05 parts of vitamin D, 0.1-200 parts of vitamin E.
3. as claimed in claim 1 or 2 a kind of with the composition for improving fecundity effect, it is characterised in that: the leaf
Acid compounds are the work of folic acid, formyl tetrahydrofolic acid, metafolin, folic acid officinal salt, folic acid or folic acid officinal salt
Property metabolite and can be metabolized in vivo and/or one or more of the substance for generating folic acid.
4. according to claim 1 a kind of with the composition for improving fecundity effect, it is characterised in that: the group
Closing raw material further includes one or more of alpha-linolenic acid, linoleic acid, haematococcus pluvialis and vitamin C.
5. according to claim 4 a kind of with the composition for improving fecundity effect, it is characterised in that: the α-
Linolenic content is 50-8000 parts；The linoleic content is 50-10000 parts；The content of the haematococcus pluvialis
It is 0.05-1000 parts；The ascorbic content is 0.05-500 parts.
6. a kind of preparation method with the composition for improving fecundity effect as described in any one in claim 1-5,
It is characterized in that: including the following steps:
(1) lycopene, zinc citrate, vitamin C, vitamin E and the haematococcus pluvialis for weighing recipe quantity are premixed, mixing
Time 10min obtains composite powder 1；
(2) vitamin D, folacin compound are carried out gradient with Se-enriched yeast to mix, obtains composite powder 2；
(3) composite powder 1 is carried out gradient with composite powder 2 to mix, obtains composite powder 3；
(4) composite powder 3 and alpha-linolenic acid, linoleic acid are subjected to total mix, incorporation time 30min, after mixing up to described one
Kind has the composition for improving fecundity effect.
7. the preparation method with the composition for improving fecundity effect according to claim 6, it is characterised in that:
Gradient mixing in the step (2), mixes for equivalent gradient, comprising the following steps:
Vitamin D, folacin compound are mixed with Se-enriched yeast according to the mass ratio of 1:1, the first premixing flour is obtained；The dimension
The gross mass of raw element D, folacin compound are equal with the quality of Se-enriched yeast；
First premixing flour is mixed with Se-enriched yeast according to the mass ratio of 1:3, the second premixing flour is obtained；
Second premixing flour is mixed with remaining Se-enriched yeast, obtains composite powder 2.
8. the preparation method with the composition for improving fecundity effect according to claim 6, it is characterised in that:
Gradient mixing in the step (3), mixes for equivalent gradient, comprising the following steps:
Composite powder 2 is mixed with composite powder 1 according to the mass ratio of 1:1, third premixing flour is obtained；The composite powder 1 and composite powder 2
Quality it is equal；
Third premixing flour is mixed with composite powder 1 according to the mass ratio of 1:3, the 4th premixing flour is obtained；
4th premixing flour is uniformly mixed with remaining composite powder 1, obtains composite powder 3.
9. according to claim 1-5 have the composition for improving fecundity effect, it is characterised in that: described
Raising fecundity effect composition can be applied to preparation improve fertility functional food in.
10. according to claim 1-5 have the composition for improving fecundity effect, it is characterised in that: institute
It can be pulvis or tablet that states, which has the dosage form for the composition for improving fecundity effect,.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811128739.5A CN109198619A (en) | 2018-09-27 | 2018-09-27 | A kind of composition and its application with raising fecundity effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811128739.5A CN109198619A (en) | 2018-09-27 | 2018-09-27 | A kind of composition and its application with raising fecundity effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109198619A true CN109198619A (en) | 2019-01-15 |
Family
ID=64981835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811128739.5A Pending CN109198619A (en) | 2018-09-27 | 2018-09-27 | A kind of composition and its application with raising fecundity effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109198619A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110179928A (en) * | 2019-05-31 | 2019-08-30 | 江西虔农农业股份有限公司 | A kind of Chinese medicine liquid and preparation method thereof for improving female endocrinic disorders |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101879184A (en) * | 2009-05-07 | 2010-11-10 | 浙江医药股份有限公司新昌制药厂 | Medicinal composition for improving reproductive capability and preparation method and application thereof |
| CN104027339A (en) * | 2014-06-12 | 2014-09-10 | 王淑芳 | Vitamin composition and application thereof in regulating ovarian function |
| US9125844B1 (en) * | 2007-09-25 | 2015-09-08 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
| CN105792818A (en) * | 2013-12-05 | 2016-07-20 | 希格马托制药工业公司 | Composition useful for promoting female fertility |
| CN105944088A (en) * | 2016-06-29 | 2016-09-21 | 中国人民解放军第三军医大学第附属医院 | Composition for regulating ovarian function and application of composition |
| US20160367500A1 (en) * | 2013-12-20 | 2016-12-22 | Fertilify Inc. | Compositions comprising vitamin c, vitamin e, and coenzyme q10 and use thereof for promoting female fertility and reproductive health |
| CN107927790A (en) * | 2017-12-08 | 2018-04-20 | 冯纪敏 | A kind of composition and its application |
| CN108403724A (en) * | 2018-04-20 | 2018-08-17 | 北京斯利安药业有限公司 | A kind of composition and preparation method thereof of adjustable mood |
-
2018
- 2018-09-27 CN CN201811128739.5A patent/CN109198619A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9125844B1 (en) * | 2007-09-25 | 2015-09-08 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
| CN101879184A (en) * | 2009-05-07 | 2010-11-10 | 浙江医药股份有限公司新昌制药厂 | Medicinal composition for improving reproductive capability and preparation method and application thereof |
| CN105792818A (en) * | 2013-12-05 | 2016-07-20 | 希格马托制药工业公司 | Composition useful for promoting female fertility |
| US20160367500A1 (en) * | 2013-12-20 | 2016-12-22 | Fertilify Inc. | Compositions comprising vitamin c, vitamin e, and coenzyme q10 and use thereof for promoting female fertility and reproductive health |
| CN104027339A (en) * | 2014-06-12 | 2014-09-10 | 王淑芳 | Vitamin composition and application thereof in regulating ovarian function |
| CN105944088A (en) * | 2016-06-29 | 2016-09-21 | 中国人民解放军第三军医大学第附属医院 | Composition for regulating ovarian function and application of composition |
| CN107927790A (en) * | 2017-12-08 | 2018-04-20 | 冯纪敏 | A kind of composition and its application |
| CN108403724A (en) * | 2018-04-20 | 2018-08-17 | 北京斯利安药业有限公司 | A kind of composition and preparation method thereof of adjustable mood |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110179928A (en) * | 2019-05-31 | 2019-08-30 | 江西虔农农业股份有限公司 | A kind of Chinese medicine liquid and preparation method thereof for improving female endocrinic disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhowmik et al. | A potential medicinal importance of zinc in human health and chronic | |
| CN107343657B (en) | Ketogenic diet formula powder | |
| CN101473900A (en) | Complete compound feed for weaning piglet | |
| CN107708683A (en) | Amino acid supplementation | |
| CN101991095A (en) | Health care product for improving sleep | |
| CN100475245C (en) | Medicine used for reducing weight, regulating fat metabolism and reducing blood fat | |
| CN106668507A (en) | Medicine for curing male infertility and preparation method thereof | |
| CN109198619A (en) | A kind of composition and its application with raising fecundity effect | |
| CN103211228A (en) | Composition for increasing bone mineral density | |
| CN101268836B (en) | Nutrition high calcium medicinal granule and preparing technique | |
| CN105998158A (en) | Health-care capsule capable of improving activity of male sperms and preparation method thereof | |
| CN109511820A (en) | A kind of health premixed feed and health mixed fodder applied to laying hen | |
| CN108294300A (en) | A kind of tranquilizing the mind dinner powder | |
| CN108065366A (en) | Walnut oil soft capsule health products with effect of supplemented calcium and preparation method thereof | |
| CN113730518A (en) | Composition for promoting diuresis and tonifying spleen and preparation method and application thereof | |
| Paninsari et al. | The relationship between the frequency of baby massage and the pattern of defecation of babies who are exclusively breastfed at bunda patimah primary clinic | |
| CN102205044A (en) | Medicament for treating cough | |
| CN109258947A (en) | A kind of compound preparation enriched blood for piglet | |
| CN1545937A (en) | Children health food containing prebiotics and preparation method thereof | |
| CN109674064A (en) | A kind of compound colostrinin and preparation method thereof | |
| CN110959824A (en) | Tranquilizing composition and preparation method thereof | |
| CN108065404A (en) | Health products and its production method with replenishing vitamins AD effects | |
| CN101653195A (en) | Vitamin composition for improving production performance of layer chicken | |
| CN109700917A (en) | Shenkangning capsules combine microelement vitamin preparation, pollen pumpkin preparation improves the application of the symptoms such as kidney-yang deficiency person's frequent urination at night | |
| CN114306492A (en) | A Chinese and western medicine for treating infantile anorexia, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190115 |
|
| RJ01 | Rejection of invention patent application after publication |